Lifeline Business Profile
Medipost said Wednesday that it has acquired a domestic patent on stem cell culture fluids that prevent hair loss. This technology exposes cord blood-derived stem cells to an artificially created hair regression environment to produce a culture solution capable of delivering pharmacological effects such as hair loss prevention.
The patent titled “Promoting the ability of stimulated stem cell culture fluid for hair growth and use thereof” relates to the development of a composition for preventing hair loss and promoting hair growth.
Stem cell cultures are not stem cells themselves but liquids obtained during the cultivation of stem cells. They contain various useful factors secreted by stem cells.
This technology exposes cord blood-derived stem cells to an artificially created hair regression environment to produce a culture solution capable of delivering pharmacological effects such as hair loss prevention.
The company has been researching stem cell cultures related to hair loss since 2013 as part of the industrial core technology development project supported by the Ministry of Trade, Industry and Energy (MOTIE) and the Korea Evaluation Institute of Industrial Technology.
The Ministry of Health and Welfare (MOHW) awarded the cultivation process with a “New Excellent Technology"certification last year.
MediPost plans to use the patented technology to develop hair loss related products. With the addition of the patent the company now owns 73 patents related to the cord blood technology.
LFLN REF: 06032018, P. 52
